Ascentage Pharma will present four poster studies at AACR 2026 highlighting preclinical efficacy and combination strategies of its key pipeline candidates. The research covers Olverembatinib in endometrial carcinoma and mantle cell lymphoma, APG-2449 in BRAF V600E–mutant tumors, and APG-5918 in small-cell lung cancer models.

Olverembatinib (HQP1351) demonstrated potent antitumor activity in endometrial carcinoma models, synergizing with standard chemotherapy by inhibiting FGFR2, PI3K/AKT, and MEK/ERK pathways and inducing DNA damage–triggered apoptosis. In mantle cell lymphoma models, Olverembatinib combined with acalabrutinib significantly enhanced apoptosis and cell cycle arrest via dual Lyn and BTK pathway inhibition and NF-κB downregulation.

APG-2449 showed selective sensitivity in BRAF V600E–mutant colorectal and melanoma cell lines, suppressing compensatory FAK signaling activated upon MAPK pathway blockade. When combined with dabrafenib and trametinib, APG-2449 synergistically enhanced antitumor effects, supporting its clinical evaluation in BRAF V600E–mutant cancers.

APG-5918, an EED inhibitor targeting PRC2-mediated epigenetic silencing, synergized with topoisomerase I inhibitors in preclinical small-cell lung cancer models by priming SLFN11 expression and overcoming chemoresistance. These findings suggest APG-5918 could enhance the efficacy of DNA-damaging therapies in relapsed or resistant SCLC cases.